Clinical trials: Pancreatic Intraepithelial Neoplasia
Pancreatic Ductal Adenocarcinoma
Evaluating LINFU™: A Noninvasive Method for Collecting Pancreatic Cells for the Early Detection of Pancreatic Cancer
Adenocyte has developed LINFU®, (Low Intensity Non-Focused Ultrasound excitation of the pancreas) as a method of identifying early, asymptomatic pancreatic cancer and its noninvasive precancerous lesions.
- Trial name
- NCT04793633
- Testing
- LINFU™ Technique
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Adenocyte, LLC
Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm
Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with early diagnosis crucial for improving survival. Due to the absence of effective screening methods, most patients are diagnosed at advanced stages.
- Conditions
- Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, High-grade Pancreatic Intraepithelial Neoplasia, PDAC - Pancreatic Ductal Adenocarcinoma
- Trial name
- AI-LDCT-PC (NCT07117045)
- Testing
- Diagnostic Evaluation for Positive AI Findings
- Where
- 5 sites in China
- Volunteers
- 400,000 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Cancer Risk, Cancer Predisposition Syndrome
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member…
- Conditions
- Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors
- Trial name
- NCT05463796
- Testing
- Samples
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort
Pancreatic ductal adenocarcinoma (PDAC) remains a therapeutic challenge with 5-year survival rates of 13%, primarily attributable to advanced-stage diagnosis (AJCC Stage III/IV in >80% of cases).
- Conditions
- Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraepithelial Neoplasias, Intraductal Papillary Mucinous Neoplasm
- Trial name
- AI-PANC (NCT06638866)
- Testing
- PDAC, Pancreatic precursor lesions
- Where
- 3 sites in China
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Pancreatic Adenocarcinoma, Pancreatic Intraepithelial Neoplasia
The LINFU® U.S. Registry for the Detection of Asymptomatic Pancreatic Ductal Adenocarcinoma
Adenocyte has developed LINFU®, (Low Intensity Non-Focused Ultrasound excitation of the pancreas) as a method of identifying early, asymptomatic pancreatic cancer and its noninvasive precancerous lesions.
- Trial name
- NCT06157671
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Adenocyte, LLC
Pancreatic Ductal Adenocarcinoma (PDAC), Intraductal Papillary Mucinous Neoplasm of Pancreas
Predictive Biomarkers for Early Diagnosis of Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic ductal adenocarcinoma (PDAC) is one of the cancers with the poorest prognosis and is often diagnosed at an advanced stage, resulting in very low 5-year survival rates.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Intraductal Papillary Mucinous Neoplasm of Pancreas, Pancreatic Intraepithelial Neoplasia
- Trial name
- B-PDAC (NCT07709052)
- Volunteers
- 180 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
The LINFU® U.S. Registry for the in the General Population Without Risk Factors
Adenocyte has developed LINFU®, (Low Intensity Non-Focused Ultrasound excitation of the pancreas) as a method of identifying early, asymptomatic pancreatic cancer and its noninvasive precancerous lesions..
- Conditions
- Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Dysplasia
- Trial name
- NCT06276803
- Testing
- LINFU®
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Adenocyte, LLC
Pancreatic Cancer
Pancreatic Intraepithelial Neoplasia (PanIN) and the Association With Recurrence of Pancreatic Adenocarcinoma
The research purpose of this project is to create a registry, and blood and tissue bank for individuals at high-risk for pancreatic cancer.
- Trial name
- NCT01219829
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Columbia University